Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators in chronic renal failure.

José R Weisinger1, Ita Pfeferman Heilberg, Eddy Hernández

  • 1Division of Nephrology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela. jweising@telcel.net.ve

Kidney International. Supplement
|May 20, 2003
PubMed
Summary

Selective estrogen receptor modulators (SERMs) like raloxifene show promise for treating osteoporosis in postmenopausal women undergoing dialysis. These agents improve bone mineral density and lipid profiles, offering an alternative to hormone replacement therapy (HRT).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rhabdomyolysis-Induced Resistant Hypercalcemia During the Recovery Phase of Acute Kidney Injury.

Cureus·2026
Same author

Nephrocalcinosis: unveiling renal tubulopathies in the genomic era.

Jornal brasileiro de nefrologia·2026
Same author

Cardiovascular Autonomic Control in Normotensive Patients with Autosomal Dominant Polycystic Kidney Disease.

Kidney360·2025
Same author

Effects of a high-fat diet on gut microbiota and possible implications for bone health in male Wistar rats.

Lipids·2025
Same author

Brazilian Guidelines on evaluation and clinical management of Nephrolithiasis: Brazilian Society of Nephrology.

Jornal brasileiro de nefrologia·2025
Same author

Kabuki and CHARGE syndromes: overlapping symptoms and diagnostic challenges.

Einstein (Sao Paulo, Brazil)·2025

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Metabolism

Background:

  • Postmenopausal women on dialysis face risks of renal osteodystrophy and osteoporosis.
  • Hormone replacement therapy (HRT) poses risks in uremic women due to altered estradiol pharmacokinetics.
  • Selective estrogen receptor modulators (SERMs) offer estrogen-like benefits for bone and lipids without HRT's adverse effects.

Purpose of the Study:

  • To review the effects of the SERM raloxifene on bone and lipid metabolism in osteoporotic postmenopausal women on dialysis.
  • To investigate if estrogen receptor (ER) gene polymorphism predicts bone mineral density (BMD) response to raloxifene.

Main Methods:

  • Review of recent data on raloxifene's effects in hemodialyzed osteoporotic postmenopausal women.
  • Analysis of estrogen receptor (ER) gene polymorphism to assess its predictive value for BMD response.

Related Experiment Videos

Main Results:

  • Raloxifene treatment increased trabecular bone mineral density (BMD) and decreased bone resorption markers in hemodialyzed women.
  • Significant reductions in LDL-cholesterol were observed.
  • Homozygous women for P or x alleles of the ER gene (PP/xx genotypes) showed a better BMD response to raloxifene compared to Pp/Xx genotypes.

Conclusions:

  • Raloxifene is a potential therapeutic alternative to HRT for postmenopausal women with renal failure.
  • SERMs, in general, may offer a safer and effective treatment option for osteoporosis in this patient population.